Why the study?
Does adjuvant chemotherapy with vincristine, actinomycin D, and cyclophosphamide improve disease-free survival in patients with non-metastatic osteosarcoma following surgical amputation?
Does adjuvant chemotherapy with vincristine, actinomycin D, and cyclophosphamide improve disease-free survival in patients with non-metastatic osteosarcoma following surgical amputation?
A 3-drug adjuvant chemotherapy regimen (vincristine, actinomycin D, cyclophosphamide) resulted in a 33% disease-free survival rate at 54+ months in patients with non-metastatic osteosarcoma post-amputation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for adjuvant chemotherapy in osteosarcoma; does not support practice change without randomized data.
Twelve patients with osteosarcoma but without metastases were treated with adjuvant chemotherapy following surgical amputation for the primary lesion. The chemotherapy regimen utilized vincristine, actinomycin D, and cyclophosphamide (in high pulse doses) administered intermittently over a 55-week period. Four of the 12 patients (33%) are surviving with no evidence of disease 54 months or longer from time of surgery. These results suggest that the 3-drug combination used in this study should be considered in the formulation of future multidrug adjuvant chemotherapy programs in the management of patients with osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Sutow et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: